Compare IOSP & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IOSP | GENB |
|---|---|---|
| Founded | 1938 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1998 | N/A |
| Metric | IOSP | GENB |
|---|---|---|
| Price | $76.75 | $12.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $93.00 | $23.20 |
| AVG Volume (30 Days) | 167.5K | ★ 321.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 228.87 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | ★ $1,778,000,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.10 | $16.58 |
| P/E Ratio | $16.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $65.51 | $11.00 |
| 52 Week High | $95.55 | $14.21 |
| Indicator | IOSP | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 60.34 | 52.76 |
| Support Level | $74.76 | $11.39 |
| Resistance Level | $77.08 | $13.40 |
| Average True Range (ATR) | 1.87 | 0.70 |
| MACD | 0.30 | 0.06 |
| Stochastic Oscillator | 86.00 | 73.45 |
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Performance Chemicals segment that derives maximum revenue, provides technology-based solutions for its customers' processes or products in personal care, home care, agrochemical, construction, mining and other industrial markets. The Fuel Specialties segment develops, manufactures, blends, markets and supplies a range of specialty chemical products used as additives in diesel, jet, marine, fuel oil and other fuels. The Oilfield Services segment develops and markets chemical solutions for drilling, completion, production, DRA and oil and gas applications.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.